ZyversaREV_cmyk.jpg
ZyVersa Therapeutics Announces Publication Demonstrating That Plasma Levels of NLRP3 Inflammasomes Correlate with Progression of Diabetic Kidney Disease in Patients with Type 2 Diabetes
07 déc. 2023 11h20 HE | ZyVersa Therapeutics
Plasma NLRP3 inflammasomes are significantly elevated in early-stage diabetic kidney disease, and levels progressively increase as kidney function worsens.